Skip to main content
. 2019 May 14;39(5):BSR20190027. doi: 10.1042/BSR20190027

Figure 4. ROC analyses of protein to distinguish adverse efficacy from NPC patients who receive radiotherapy.

Figure 4

((A) SPARC+C4B+FAM173A; (B) SERPIND1+ C4B + PPIB; (C) C4B+PPIB+FAM173A; (D) SPARC+SERPIND1+C4B; (E) SPARC+SERPIND1+FAM173A; (F) SERPIND1+C4B+FAM173A; (G) SPARC+SERPIND1+PPIB; (H) SPARC+PPIB+FAM173A; (I) SERPIND1+PPIB+FAM173A).